Ask about this productRelated genes to: GSTA1 protein
- Gene:
- GSTA1 NIH gene
- Name:
- glutathione S-transferase alpha 1
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 6p12.2
- Locus Type:
- gene with protein product
- Date approved:
- 1991-12-06
- Date modifiied:
- 2015-09-10
Related products to: GSTA1 protein
Related articles to: GSTA1 protein
- Adenomyosis, a common gynecologic condition of the uterus, affects women with diverse symptoms including pain. Traditionally evaluated pathologically, advanced imaging modality has led to more diagnoses including asymptomatic women. This noninvasive diagnosis has raised questions about disease progression and symptom development. This study aimed to investigate the cellular and molecular patterns associated with adenomyosis and adenomyosis-related pain, focusing on inflammatory processes. We employed an integrative, retrospective bioinformatic design combining publicly available bulk RNA-sequencing data from adenomyotic and control endometrium and myometrium with single-cell RNA-sequencing data from adenomyosis patients stratified by the presence of pain. - Source: PubMed
Publication date: 2026/07/08
Kwon KanghyunKwon Ji YoungSheen KisungYu SanghyeonKim Ye-AhYoo Eun HeeLee KiwonKim Man S - A better understanding of the response of granulosa cells to exogenous hormone stimulation and how this impacts the complex interplay between the granulosa cells and the oocyte is crucial for the optimal management of infertile couples seeking IVF treatment. - Source: PubMed
Publication date: 2026/06/10
Medica AlexaKim Matthew EHung Wei-TingSohni AbhishekDuleba AntoniTan KunWilkinson Miles F - Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) followed by post-transplant cyclophosphamide (CPA) treatment is an avenue to expand the pool of potential donors. This study aimed to investigate whether the gene polymorphisms related to CPA activation and metabolism are associated with the clinical outcomes of patients receiving haplo-HSCT. - Source: PubMed
Publication date: 2026/06/13
Chen Ding-PingLin Tung-LiangWu Gem Huai-ChuehLin Wei-TzuHsu Fang-PingTseng Ching-Ping - There is growing evidence supporting the anti-inflammatory activity of plant sterols (PS) in preclinical models of intestinal inflammation. However, the underlying mechanisms driving these beneficial effects remain incompletely understood. This study investigates the transcriptional modulatory activity of a PS food supplement (PS-FS) on genes associated with the cellular antioxidant defense system and tight junction (TJ) proteins. A double-chamber coculture model with differentiated Caco-2 cells (apical) and RAW264.7 macrophages (basolateral) was used. Bioaccessible fraction (BF) of PS-FS was obtained following the INFOGEST 2.0 simulated gastrointestinal digestion. A 1/20 dilution of BF was applied to the apical chamber for 90 min, followed by lipopolysaccharide (LPS) stimulation (1 µg/mL, 24 h) on the basolateral side. The interaction between PS-FS and budesonide was also evaluated. The gene expression of Nrf2 (NFE2L2), glutathione S-transferase A1 (GSTA1), NAD(P)H quinone dehydrogenase 1 (NQO1), and heme oxygenase 1 (HMOX-1) was quantified. Additionally, gene expression of TJ-related genes (CLDN1, CLDN3, CLDN4, OCLN, and TJP1) was quantified. Pretreatment with PS-FS significantly increased expression of GSTA1 (26.8%) and HMOX-1 (124.4%) compared to LPS + digestion blank. Furthermore, there was a trend toward increased expression of NFE2L2 and NQO1. Similarly, PS-FS enhanced expression of CLDN3 (33.0%), CLDN4 (211.7%), OCLN (57.1%), and TJP1 (98.9%). However, co-treatment of budesonide and PS-FS resulted in antagonistic interactions. These findings indicate that PS-FS modulates gene expression associated with antioxidant responses and intestinal barrier integrity-related pathways, suggesting to be further developed as a dietary strategy to support the management of inflammatory bowel disease PRACTICAL APPLICATIONS: This research supports the potential use of plant sterol-based food supplements in products aimed at supporting intestinal health. The results suggest that these supplements could help strengthen the gut barrier and support the body's natural antioxidant defenses during intestinal inflammation. - Source: PubMed
Makran MussaGiardina Ilenia ConcettaGarcia-Llatas GuadalupeAttanzio AlessandroCilla Antonio - : Postmenopausal osteoporosis (PMOP) is a common metabolic bone disorder characterized by disrupted bone remodeling due to estrogen deficiency. Erxian Decoction (EXD), a traditional Chinese medicine formula, has shown clinical efficacy against PMOP, but its bioactive constituents and molecular mechanisms remain elusive. : The therapeutic effects of EXD were evaluated in ovariectomized (OVX) mice using micro-CT and bone histomorphometry. Absorbed constituents of EXD were identified by UHPLC-Q analysis. Network pharmacology and quantitative proteomics were integrated to predict the key pathways and targets. The candidate target was validated by in vivo assays, including Western blot, glutathione (GSH) levels, glutathione S-transferases (GSTs) activity, malondialdehyde (MDA), and 4-hydroxynonenal (4-HNE) levels. Molecular docking was performed to assess the binding affinity between bioactive components and the target protein. : EXD treatment significantly ameliorated bone microarchitecture deterioration and restored bone remodeling balance in OVX mice. A total of 137 core absorbed constituents of EXD were identified. Integrated network pharmacology and proteomics analyses revealed that EXD primarily modulates the glutathione metabolism pathway to counteract oxidative stress. Glutathione S-transferase A1 (GSTA1) was pinpointed as a potential target. In vivo experiments confirmed that EXD upregulated GSTA1 expression, restored total GSTs activity, replenished GSH reserves, and reduced MDA and 4-HNE levels. Molecular docking demonstrated stable protein-ligand interactions between bioactive components of EXD and GSTA1. : EXD alleviates PMOP by activating GSTA1-mediated glutathione metabolism and suppressing oxidative stress. These findings provide a mechanistic basis for the clinical application of EXD in treating PMOP. - Source: PubMed
Publication date: 2026/04/30
Li JingdiZuo JiapoZou YaotingWeng YaoqiangLin KaiyangZou YihangYe XuleqinMa DezunYan Hui